TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers - PubMed (original) (raw)
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers
Florence Le Calvez et al. Cancer Res. 2005.
Abstract
TP53 mutations are common in lung cancers of smokers, with high prevalence of G:C-to-T:A transversions generally interpreted as mutagen fingerprints of tobacco smoke. In this study, TP53 (exons 5-9) and KRAS (codon 12) were analyzed in primary lung tumors of never (n = 40), former (n = 27), and current smokers (n = 64; mainly heavy smokers). Expression of p53, cyclooxygenase-2 (Cox-2), and nitrotyrosine (N-Tyr), a marker of protein damage by nitric oxide, were analyzed by immunohistochemistry. TP53 mutations were detected in 47.5% never, 55.6% former, and 77.4% current smokers. The relative risk for mutation increased with tobacco consumption (P(linear trend) < 0.0001). G:C-to-T:A transversions (P = 0.06, current versus never smokers) and A:T-to-G:C transitions (P = 0.03, former versus never smokers) were consistently associated with smoking. In contrast, G:C-to-A:T transitions were associated with never smoking (P = 0.02). About half of mutations in current smokers fell within a particular domain of p53 protein, suggesting a common structural effect. KRAS mutations, detected in 20 of 131 (15.3%) cases, were rare in squamous cell carcinoma compared with adenocarcinoma [relative risk (RR), 0.2; 95% confidence interval (95% CI), 0.07-1] and were more frequent in former smokers than in other categories. No significant differences in Cox-2 expression were found between ever and never smokers. However, high levels of N-Tyr were more common in never than ever smokers (RR, 10; 95% CI, 1.6-50). These results support the notion that lung tumorigenesis proceeds through different molecular mechanisms according to smoking status. In never smokers, accumulation of N-Tyr suggests an etiology involving severe inflammation.
Similar articles
- p53 and K-ras mutations in lung cancers from former and never-smoking women.
Vähäkangas KH, Bennett WP, Castrén K, Welsh JA, Khan MA, Blömeke B, Alavanja MC, Harris CC. Vähäkangas KH, et al. Cancer Res. 2001 Jun 1;61(11):4350-6. Cancer Res. 2001. PMID: 11389059 - p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer.
Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, Constantinescu V, Fortes C, Benhamou S. Husgafvel-Pursiainen K, et al. Cancer Res. 2000 Jun 1;60(11):2906-11. Cancer Res. 2000. PMID: 10850436 - Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Gealy R, et al. Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):297-302. Cancer Epidemiol Biomarkers Prev. 1999. PMID: 10207632 - The TP53 gene, tobacco exposure, and lung cancer.
Toyooka S, Tsuda T, Gazdar AF. Toyooka S, et al. Hum Mutat. 2003 Mar;21(3):229-39. doi: 10.1002/humu.10177. Hum Mutat. 2003. PMID: 12619108 Review. - Lung cancer in never smokers: a review.
Subramanian J, Govindan R. Subramanian J, et al. J Clin Oncol. 2007 Feb 10;25(5):561-70. doi: 10.1200/JCO.2006.06.8015. J Clin Oncol. 2007. PMID: 17290066 Review.
Cited by
- KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K, Posa MK, Shenoy RP, Roychoudhury S. Mondal K, et al. Cells. 2024 Jul 19;13(14):1221. doi: 10.3390/cells13141221. Cells. 2024. PMID: 39056802 Free PMC article. Review. - Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T, Liu J, Zhou Y, Huang S, Wang D, Chen J, Fu Y, He P. Li T, et al. Cancer Med. 2024 May;13(10):e7227. doi: 10.1002/cam4.7227. Cancer Med. 2024. PMID: 38770632 Free PMC article. - A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.
Xing X, Li L, Sun M, Zhu X, Feng Y. Xing X, et al. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241249168. doi: 10.1177/17534666241249168. Ther Adv Respir Dis. 2024. PMID: 38757628 Free PMC article. - Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening.
Daylan AEC, Miao E, Tang K, Chiu G, Cheng H. Daylan AEC, et al. Lung. 2023 Dec;201(6):521-529. doi: 10.1007/s00408-023-00661-3. Epub 2023 Nov 16. Lung. 2023. PMID: 37973682 Review. - A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers.
Hamouz M, Hammouz RY, Bajwa MA, Alsayed AW, Orzechowska M, Bednarek AK. Hamouz M, et al. Int J Mol Sci. 2023 Aug 28;24(17):13314. doi: 10.3390/ijms241713314. Int J Mol Sci. 2023. PMID: 37686122 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous